Jeffrey Nau, PhD

Dr. Jeffrey Nau is President of the Eye Care Division at Viatris Inc. (NASDAQ: VTRS), a global healthcare company empowering people worldwide to live healthier at every stage of life.

Dr. Nau was previously CEO of Oyster Point Pharma, where he led the company through its initial public offering in 2019 on the Nasdaq Stock Market, executed multiple value-generating business development deals and global partnerships, in addition to having raised more than $300M+ in capital, before the company was acquired by Viatris.

Under Dr. Nau’s leadership, he launched TYRVAYA®, the first and only FDA-approved nasal spray for the treatment of the signs and symptoms of dry eye disease and expanded Oyster Point’s pipeline to include an investigational Enriched Tear Film (ETF™) Gene Therapy program with the potential to fundamentally change the way that chronic diseases of the ocular surface are treated.

Dr. Nau is not new to developing medical breakthroughs. Before joining Viatris, he held leadership positions across several pharmaceutical, medical device, and biotechnology companies, including Genentech, a subsidiary of Roche, where he served as a key stakeholder on the development and launch of multiple indications for Lucentis®, one of the biggest medical breakthroughs in the history of treating blindness. The therapy changed the treatment approach for millions of patients and generated more than $1 billion in annual sales. In addition, he helped raise more than $250 million in equity for innovative startups such as Genaera Corporation, Acuity Pharmaceuticals, and NeoVista, Inc.

Dr. Nau has a Ph.D. in Public Health and Epidemiology from Walden University, a Master of Medical Science from Drexel University’s MCP Hahnemann School of Medicine, and a Bachelor’s in Biology from Stony Brook University. He holds numerous patents and peer-reviewed publications.